NO2794859T3 - - Google Patents

Info

Publication number
NO2794859T3
NO2794859T3 NO12859499A NO12859499A NO2794859T3 NO 2794859 T3 NO2794859 T3 NO 2794859T3 NO 12859499 A NO12859499 A NO 12859499A NO 12859499 A NO12859499 A NO 12859499A NO 2794859 T3 NO2794859 T3 NO 2794859T3
Authority
NO
Norway
Application number
NO12859499A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2794859T3 publication Critical patent/NO2794859T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
NO12859499A 2011-12-22 2012-12-18 NO2794859T3 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110140361 2011-12-22
PCT/KR2012/011114 WO2013094988A1 (en) 2011-12-22 2012-12-18 Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same

Publications (1)

Publication Number Publication Date
NO2794859T3 true NO2794859T3 (ja) 2018-02-17

Family

ID=48668805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12859499A NO2794859T3 (ja) 2011-12-22 2012-12-18

Country Status (9)

Country Link
US (1) US9834753B2 (ja)
EP (1) EP2794859B1 (ja)
JP (1) JP6010136B2 (ja)
KR (1) KR101644984B1 (ja)
CN (1) CN104204194B (ja)
AU (1) AU2012354438B2 (ja)
ES (1) ES2652666T3 (ja)
NO (1) NO2794859T3 (ja)
WO (1) WO2013094988A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923879B (zh) * 2014-04-29 2016-03-30 湖北华赛生物医药技术有限公司 一种nk细胞因子混合物的制备方法及其应用
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
CN104593324B (zh) * 2014-11-28 2018-04-13 广州赛莱拉干细胞科技股份有限公司 一种自然杀伤细胞的培养基及自然杀伤细胞的扩增培养方法
KR101706524B1 (ko) * 2014-12-03 2017-02-14 주식회사 녹십자랩셀 안정성 높은 자연살해세포의 효율적인 제조방법
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN104789527B (zh) * 2015-05-15 2018-05-29 江苏杰晟生物科技有限公司 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品
KR101909879B1 (ko) * 2015-06-24 2018-10-19 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
WO2016209021A1 (ko) * 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
WO2017003153A1 (ko) * 2015-06-29 2017-01-05 주식회사 녹십자랩셀 제대혈 단핵세포 또는 이로부터 유래된 세포로부터 자연살해세포를 제조하는 방법
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US10975149B2 (en) * 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
KR102175256B1 (ko) * 2016-02-01 2020-11-06 주식회사 녹십자랩셀 세포의 동결보존용 배지 조성물 및 이의 용도
CA3011374A1 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
KR101683614B1 (ko) * 2016-02-15 2016-12-07 신동혁 Nk세포배양용 배지첨가키트 및 상기 키트를 이용한 nk세포배양방법
CN105754942A (zh) * 2016-05-18 2016-07-13 天津普瑞赛尔生物科技有限公司 一种体外扩增nk细胞的方法及其获得的nk细胞
CN105925527A (zh) * 2016-05-19 2016-09-07 成都百赛泰科生物科技有限公司 一种用于制备nk细胞的试剂盒及其应用方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106434554B (zh) * 2016-08-31 2019-07-26 北京同立海源生物科技有限公司 Nk细胞的制备方法
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
WO2018088875A2 (ko) * 2016-11-14 2018-05-17 주식회사 파이안에스테틱스 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물
CN106834227B (zh) * 2016-12-26 2020-01-24 深圳精准医疗科技有限公司 自然杀伤细胞的体外纯化方法
EP3399027A1 (en) * 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
KR102460173B1 (ko) * 2017-05-26 2022-10-31 주식회사 지씨셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
CN107267463A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种针对乳腺癌的Car‑NK细胞制备方法
CN107595865B (zh) * 2017-09-25 2018-08-14 徐州佳生医药科技有限公司 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
KR102014467B1 (ko) * 2017-12-14 2019-08-26 (주)녹십자웰빙 아토피성 피부염, 탈모, 상처 또는 피부 주름의 개선용 화장료 조성물 및 약학 조성물
US20210040451A1 (en) * 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. NATURAL KILLER CELL PRODUCTION PROCESS AND COMPOSITION FOR CANCER TREATMENT
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
SG11202010763VA (en) * 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN109762785B (zh) * 2018-12-10 2022-06-24 苏州近岸蛋白质科技股份有限公司 一种高效应用于人nk细胞非滋养层体外培养的方法
KR102419960B1 (ko) * 2019-03-15 2022-07-13 (주) 테라베스트 세포 조성물, 이의 제조 방법 및 이를 포함하는 아토피 예방 또는 치료용 약학 조성물
KR102137954B1 (ko) * 2019-05-16 2020-07-27 (주)녹십자셀 사이토카인 유도 살해세포를 포함하는 활성화 림프구 및 이의 제조 방법
CN110305843B (zh) * 2019-07-12 2020-06-02 赛德特生物科技开发有限公司 可以改善自身免疫性疾病的免疫细胞及其制备方法与应用
BR112022009532A2 (pt) * 2019-11-20 2022-08-02 Gi Cell Inc Composição para cultura de células exterminadoras naturais e método para preparação de células exterminadoras naturais usando a mesma
KR20220119611A (ko) * 2019-11-29 2022-08-30 주식회사 엔케이맥스 천연 살해 세포의 제조 방법 및 이의 조성물
KR102111283B1 (ko) 2019-12-12 2020-05-15 주식회사 이뮤니스바이오 면역세포의 진탕 배양 방법
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
KR20220036287A (ko) * 2020-09-15 2022-03-22 주식회사 티에스바이오 고순도 및 고효율의 자연살해세포 제조방법 및 이의 용도
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
KR20230039789A (ko) * 2021-09-10 2023-03-21 한국생명공학연구원 자연살해세포의 제조방법 및 이의 감염성 질환 예방 또는 치료 용도
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
WO2023147347A2 (en) * 2022-01-25 2023-08-03 The Regents Of The University Of California Crispr-mediated deletion of fli1 in nk cells
WO2023240182A1 (en) 2022-06-08 2023-12-14 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766601A (en) * 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
CA2247131A1 (en) * 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
WO1998006822A1 (en) * 1996-08-08 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. Culture medium and use of the same
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
WO2005007116A2 (en) * 2003-07-18 2005-01-27 Valeocyte Therapies Llc Artificial antigen presenting cell devices
KR20080008060A (ko) * 2006-07-19 2008-01-23 전남대학교산학협력단 자연살해세포의 제조 방법
EP2052075A4 (en) * 2006-08-23 2010-05-26 Binex Co Ltd METHOD OF PREPARING ACTIVATED LYMPHOCYTES FOR IMMUNOTHERAPY
CN101302491B (zh) * 2007-05-09 2011-09-14 王歈 高效扩增活化淋巴细胞的方法和培养系统
JP4953403B2 (ja) * 2007-11-05 2012-06-13 恒雄 倉持 がん免疫療法用細胞の製造方法
KR101035556B1 (ko) * 2008-05-22 2011-05-23 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물
KR20090127974A (ko) 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
KR101043588B1 (ko) 2008-07-25 2011-06-22 재단법인 철원플라즈마 산업기술연구원 내 플라즈마 세라믹 코팅막 형성방법
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
DK2411507T3 (da) * 2009-03-26 2020-01-06 Cellprotect Nordic Pharmaceuticals Ab Ekspansion af nk-celler
US9062287B2 (en) * 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
WO2011080740A1 (en) * 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
EP2702145A1 (en) * 2011-04-28 2014-03-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for preparing accessory cells and uses thereof for preparing activated nk cells

Also Published As

Publication number Publication date
KR20140123503A (ko) 2014-10-22
AU2012354438A1 (en) 2014-07-10
CN104204194A (zh) 2014-12-10
EP2794859A4 (en) 2015-05-27
ES2652666T3 (es) 2018-02-05
JP2015502756A (ja) 2015-01-29
US20150118207A1 (en) 2015-04-30
EP2794859A1 (en) 2014-10-29
US9834753B2 (en) 2017-12-05
WO2013094988A1 (en) 2013-06-27
KR101644984B1 (ko) 2016-08-12
AU2012354438B2 (en) 2016-03-31
JP6010136B2 (ja) 2016-10-19
EP2794859B1 (en) 2017-09-20
CN104204194B (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
NO2794859T3 (ja)
AP3853A (ja)
BR112013031251A2 (ja)
BR112013024383A2 (ja)
BR112013017670A2 (ja)
BR112013027830A2 (ja)
BR112013028733A2 (ja)
AP2016009466A0 (ja)
BR112013031556A2 (ja)
BR112013032380A2 (ja)
BR112013032377A2 (ja)
BR112013032368A2 (ja)
BR112013027836A2 (ja)
BR112013032392A2 (ja)
BR112013025487A2 (ja)
BR112013017878A2 (ja)
BR112013027871A2 (ja)
BR112013032394A2 (ja)
BR112013030734A2 (ja)
AP3777A (ja)
BR102012019800A2 (ja)
BR102012006249A2 (ja)
AP3936A (ja)
BR112013027874A2 (ja)
BR112013027764A2 (ja)